MYOS RENS is evaluating the genotypic characteristics and molecular pathways that contribute to the changes seen in muscle and inflammatory disease states associated with sarcopenia and related disorders.
MYOS RENS takes its responsibility to the environment and the community very seriously. MYOS RENS is committed to being a good corporate citizen and welcomes suggestions on enhancing our contributions in this regard.
Net Proceeds of $1.1 Million in Non-dilutive Funding Expected
CEDAR KNOLLS, N.J., Dec. 6, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean [...]
Conference Call to be Held Thursday, November 15, 2018, at 10:30am ET
CEDAR KNOLLS, N.J., Nov. 14, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, the natural food product that helps build lean muscle in conjunction with resistance training, [...]